07:08 AM EDT, 09/16/2025 (MT Newswires) -- Novo Nordisk ( NVO ) said Tuesday a phase 3 Redefine subanalysis found once-weekly cagrilintide 2.4 mg produced mean weight loss of roughly 11.8% versus 2.3% with a placebo at 68 weeks.

The drug will advance to a dedicated phase 3 program in Q4, the company said. About 31.6% of participants on cagrilintide achieved at least 15% weight loss versus 4.7% on placebo, the company said.

Cagrilintide caused mild to moderate gastrointestinal side effects; nausea led 1% of participants to halt treatment versus 0.1% for placebo, Novo said.

Shares of the company were up 2.7% in recent Tuesday premarket activity.